よむ、つかう、まなぶ。
参考資料15 COVID-19 vaccine safety update; Primary series in young children and booster doses in older children and adults, ACIP September 1, 2022 (20 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000208910_00052.html |
| 出典情報 | 第85回厚生科学審議会予防接種・ワクチン分科会副反応検討部会、令和４年度第14回薬事・食品衛生審議会薬事分科会医薬品等安全対策部会安全対策調査会（合同開催）（10／7）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
U.S. reports to VAERS following 1st and 2nd mRNA COVID-19
booster vaccinations* (as of August 21, 2022)
Booster
dose
Doses
admin†
1st booster
1,153,611
Total Median
reports
age
Male‡
n (%)
Female‡
n (%)
Non-serious
n (%)
Serious
n (%)
369 (51)
348 (48)
723 (99)
4 (1)
727
9 years
1st booster 102,063,616
64,265
53 years
21,841 (34) 41,234 (64)
57,048 (89)
7,217 (11)
2nd booster
12,619
68 years
4,556 (36)
11,895 (94)
724 (6)
(5–11 years)
(≥12 years)
(≥50 years)
20,145,400
7,973 (63)
* Among persons receiving Pfizer-BioNTech dose 3: children ages 5–11 years vaccinated during May 17–August 21, 2022; children and adolescents ages 12–15 years vaccinated
during January 3–August 21, 2022, and ages 16–17 years vaccinated during December 9, 2021–August 21, 2022; adults ages ≥18 years vaccinated during September 22, 2021–
August 21, 2022. Among persons receiving Moderna dose 3: adults ages ≥18 years vaccinated during October 20, 2021–August 21, 2022. Among persons ages ≥50 years: dose 4
Pfizer-BioNTech or Moderna vaccine received during March 29–August 21, 2022.
†
Doses of Pfizer-BioNTech dose 3 administered among children ages 5–11 years during June 16–August 18, 2022; children and adolescents ages 12–15 years during January 6–
August 18, 2022; adolescents ages 16–17 years during December 9, 2021–August 18, 2022; adults ages ≥18 years during September 22, 2021–August 18, 2022. Doses of Moderna
dose 3 administered among adults ages ≥18 years during October 28, 2021–August 18, 2022. Among adults ages ≥50 years, 2nd booster dose of Pfizer-BioNTech or Moderna
vaccine administered during March 28–August 18, 2022.
‡ Sex
was not reported in approximately 2% of reports.
20
booster vaccinations* (as of August 21, 2022)
Booster
dose
Doses
admin†
1st booster
1,153,611
Total Median
reports
age
Male‡
n (%)
Female‡
n (%)
Non-serious
n (%)
Serious
n (%)
369 (51)
348 (48)
723 (99)
4 (1)
727
9 years
1st booster 102,063,616
64,265
53 years
21,841 (34) 41,234 (64)
57,048 (89)
7,217 (11)
2nd booster
12,619
68 years
4,556 (36)
11,895 (94)
724 (6)
(5–11 years)
(≥12 years)
(≥50 years)
20,145,400
7,973 (63)
* Among persons receiving Pfizer-BioNTech dose 3: children ages 5–11 years vaccinated during May 17–August 21, 2022; children and adolescents ages 12–15 years vaccinated
during January 3–August 21, 2022, and ages 16–17 years vaccinated during December 9, 2021–August 21, 2022; adults ages ≥18 years vaccinated during September 22, 2021–
August 21, 2022. Among persons receiving Moderna dose 3: adults ages ≥18 years vaccinated during October 20, 2021–August 21, 2022. Among persons ages ≥50 years: dose 4
Pfizer-BioNTech or Moderna vaccine received during March 29–August 21, 2022.
†
Doses of Pfizer-BioNTech dose 3 administered among children ages 5–11 years during June 16–August 18, 2022; children and adolescents ages 12–15 years during January 6–
August 18, 2022; adolescents ages 16–17 years during December 9, 2021–August 18, 2022; adults ages ≥18 years during September 22, 2021–August 18, 2022. Doses of Moderna
dose 3 administered among adults ages ≥18 years during October 28, 2021–August 18, 2022. Among adults ages ≥50 years, 2nd booster dose of Pfizer-BioNTech or Moderna
vaccine administered during March 28–August 18, 2022.
‡ Sex
was not reported in approximately 2% of reports.
20